세계의 신약개발 AI 시장 - 규모, 점유율, 성장 분석 : 컴포넌트별, 기술별, 용도별, 지역별 산업 예측(2024-2031년)
AI In Drug Discovery Market Size, Share, Growth Analysis, By Component (Software, Services), By Technology (Machine Learning, Deep Learning), By Application, By Region - Industry Forecast 2024-2031
상품코드:1619278
리서치사:SkyQuest
발행일:2024년 12월
페이지 정보:영문 157 Pages
라이선스 & 가격 (부가세 별도)
한글목차
신약개발 AI 세계 시장 규모는 2022년에 18억 달러로 평가되었고, 2023년의 23억 4,000만 달러에서 2031년에는 193억 5,000만 달러로 성장할 것으로 예상되며 예측 기간중(2024-2031년)의 CAGR은 30.2%로 나타날 전망입니다.
생명과학 분야에서 혁신적인 치료법의 요구와 제조 능력을 강화하여 AI를 활용한 의약품 개발 솔루션 수요가 급증하고 있습니다. 화합물의 스크리닝과 임상시험의 성공률을 향상시킴으로써 창약에 혁명을 가져오고 있습니다. 임상시험에 대한 AI의 통합은 정확성, 효율성을 높이고 개발주기를 단축함으로써 상황을 일변시키고 있습니다. 특히 제약기업과 AI기업과의 전략적 제휴는 크게 증가하고 있으며, 약물의 신속화에 있어서의 AI의 중요한 역할이 부각되고 있습니다.
목차
소개
조사의 목적
조사 범위
정의
조사 방법
정보 조달
2차 데이터와 1차 데이터의 방법
시장 규모 예측
시장의 전제조건과 제한
주요 요약
세계 시장 전망
공급과 수요 동향 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
성장 촉진요인과 기회
억제요인과 과제
Porter's Five Forces 분석과 영향
경쟁 기업간 경쟁 관계
대체품의 위협
구매자의 협상력
신규 진입업자의 위협
공급기업의 협상력
주요 시장 인사이트
중요성공요인
경쟁도
주요 투자 기회
시장 생태계
시장의 매력 지수(2023년)
PESTEL 분석
거시경제지표
밸류체인 분석
가격 분석
기술의 진보
규제 상황
특허 분석
사례 연구
스타트업 분석
신약개발 AI 시장 규모 : 컴포넌트별 & CAGR(2024-2031)
시장 개요
소프트웨어
머신러닝
딥러닝
기타
서비스
구현 서비스
유지보수 및 지원
기타
신약개발 AI 시장 규모 : 기술별 & CAGR(2024-2031)
시장 개요
머신러닝
지도 학습
비지도 학습
강화 학습
딥러닝
자연언어처리(NLP)
기타
신약개발 AI 시장 규모 : 용도별 & CAGR(2024-2031)
시장 개요
타겟 식별
분자 스크리닝
리드 최적화
전임상시험
임상시험
기타
신약개발 AI 시장 규모 : 치료 영역별 & CAGR(2024-2031)
시장 개요
종양학
신경퇴행성 질환
심혈관 질환
대사성 질환
감염증
기타
신약개발 AI 시장 규모 : 최종 용도별 & CAGR(2024-2031)
시장 개요
제약·바이오테크놀러지 기업
계약연구기관(CRO)
학술연구기관
기타
신약개발 AI 시장 규모 & CAGR(2024-2031)
북미
미국
캐나다
유럽
영국
독일
스페인
프랑스
이탈리아
기타 유럽
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카
중동 및 아프리카
GCC 국가
남아프리카
기타 중동 및 아프리카
경쟁 정보
상위 5개사 비교
주요 기업의 시장 포지셔닝(2023년)
주요 시장 기업이 채용한 전략
시장의 최근 동향
기업의 시장 점유율 분석(2023년)
주요 기업의 기업 프로파일
기업 개요
제품 포트폴리오 분석
부문별 점유율 분석
수익의 전년대비 비교(2021-2023)
주요 기업 프로파일
IBM Corporation
NVIDIA Corporation
Microsoft Corporation
Exscientia
Atomwise, Inc.
BenevolentAI
Insilico Medicine
Cyclica
Schrodinger, Inc.
Cloud Pharmaceuticals, Inc.
BioSymetrics
XtalPi Inc.
Deep Genomics
Numerate, Inc.
Berg LLC
OWKIN, Inc.
TwoXAR, Inc.
Verge Genomics
Recursion Pharmaceuticals
PathAI
결론과 권장사항
JHS
영문 목차
영문목차
Global AI in Drug Discovery Market size was valued at USD 1.80 billion in 2022 and is poised to grow from USD 2.34 billion in 2023 to USD 19.35 billion by 2031, growing at a CAGR of 30.2% during the forecast period (2024-2031).
The demand for AI-powered drug development solutions is surging in response to the need for innovative medical cures and enhanced manufacturing capabilities in the life sciences sector. Technologies like machine learning and deep learning are revolutionizing drug discovery by improving initial compound screening and clinical trial success rates. With a growing influx of funding, investments, and startups focused on AI applications, the market is poised for accelerated growth. AI's integration into clinical trials is transforming the landscape by enhancing accuracy, efficiency, and reducing development cycles. Notably, strategic collaborations between pharma companies and AI firms rose significantly from 2015 to 2020, highlighting AI's vital role in expediting drug discovery. The versatility of AI technologies, including data mining and customization, further propels this upward trajectory.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ai In Drug Discovery market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Ai In Drug Discovery Market Segmental Analysis
Global AI in Drug Discovery Market is segmented by component, technology, application, therapeutic area, end use and region. Based on component, the market is segmented into software and services. Based on technology, the market is segmented into machine learning, deep learning, natural language processing (NLP) and others. Based on application, the market is segmented into target identification, molecule screening, lead optimization, preclinical testing, clinical trials and others. Based on therapeutic area, the market is segmented into oncology, neurodegenerative diseases, cardiovascular diseases, metabolic diseases, infectious diseases and others. Based on end use, the market is segmented into pharmaceutical & biotechnology companies, contract research organizations (CROs), academic & research institutes and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Ai In Drug Discovery Market
A significant driver of the Global AI in Drug Discovery market is the escalating investment in medical technology. As organizations strive for rapid advancements in drug discovery, substantial funding is directed towards research and development initiatives, especially in artificial intelligence and machine learning. These technologies not only streamline the identification of viable drug candidates but also significantly shorten the duration of clinical trials. Consequently, this leads to more efficient drug development processes, resulting in drugs reaching the market faster and at a reduced cost. The focus on innovative healthcare solutions continues to propel growth in this sector, underlining its essential role in modern therapeutics.
Restraints in the Global Ai In Drug Discovery Market
One of the main obstacles hindering the global AI in drug discovery market is the challenge of data security and privacy. Given the sensitive nature of healthcare data, there is a significant risk of breaches, leading to ethical and legal concerns. Companies in this sector must navigate strict regulations regarding data privacy and cybersecurity, which can elevate operational costs and result in delays in the adoption of AI-driven drug development solutions. As a result, the apprehension surrounding data handling can impede the growth and efficiency of AI applications in the pharmaceutical industry.
Market Trends of the Global Ai In Drug Discovery Market
The global AI in drug discovery market is witnessing a significant trend driven by the increasing application of AI in preclinical and clinical research. By leveraging advanced AI models, researchers are now able to identify biomarkers for disease progression, refine clinical trial designs, and predict patient responses with greater precision. This not only mitigates the risk of trial failures but also accelerates the testing process, ensuring timely identification of promising drug candidates. Enhanced accuracy in trial procedures and improved patient enrollment strategies are further propelling this trend, positioning AI as a crucial element in revolutionizing drug development and expediting the path to market for new therapeutics.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Driver & Opportunities
Restraints & Challenges
Porters Analysis & Impact
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2023
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technological Advancement
Regulatory Landscape
Patent Analysis
Case Studies
Startup Analysis
Global AI in Drug Discovery Market Size by Component & CAGR (2024-2031)
Market Overview
Software
Machine Learning
Deep Learning
Others
Services
Implementation Services
Maintenance & Support
Others
Global AI in Drug Discovery Market Size by Technology & CAGR (2024-2031)
Market Overview
Machine Learning
Supervised Learning
Unsupervised Learning
Reinforcement Learning
Deep Learning
Natural Language Processing (NLP)
Others
Global AI in Drug Discovery Market Size by Application & CAGR (2024-2031)
Market Overview
Target Identification
Molecule Screening
Lead Optimization
Preclinical Testing
Clinical Trials
Others
Global AI in Drug Discovery Market Size by Therapeutic Area & CAGR (2024-2031)
Market Overview
Oncology
Neurodegenerative Diseases
Cardiovascular Diseases
Metabolic Diseases
Infectious Diseases
Others
Global AI in Drug Discovery Market Size by End Use & CAGR (2024-2031)
Market Overview
Pharmaceutical & Biotechnology Companies
Contract Research Organizations (CROs)
Academic & Research Institutes
Others
Global AI in Drug Discovery Market Size & CAGR (2024-2031)
North America, (Component, Technology, Application, Therapeutic Area, End Use)
US
Canada
Europe, (Component, Technology, Application, Therapeutic Area, End Use)
UK
Germany
Spain
France
Italy
Rest of Europe
Asia-Pacific, (Component, Technology, Application, Therapeutic Area, End Use)
China
India
Japan
South Korea
Rest of Asia Pacific
Latin America, (Component, Technology, Application, Therapeutic Area, End Use)
Brazil
Rest of Latin America
Middle East & Africa, (Component, Technology, Application, Therapeutic Area, End Use)